Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience.
Majidova N, Sarı M, Kahvecioglu FA, Ozcan E, Akdag MO, Dogan A, Yıldırım S, Sonusen SD, Yunusov E, Yasar A, Celebi A, Sever N, Kocaaslan E, Erel P, Agyol Y, Guren AK, Arıkan R, Isık S, Balvan O, Geredelı C, Uygun K, Hacibekiroglu I, Kostek O, Bayoglu IV. Majidova N, et al. Among authors: dogan a. Oncol Res Treat. 2024 Apr 2:1-7. doi: 10.1159/000537988. Online ahead of print. Oncol Res Treat. 2024. PMID: 38565096
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.
Yildirim S, Dogan A, Akdag G, Yüksel Yasar Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, Alan O, Coban Kokten S, Isik D, Surmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Yildirim S, et al. Among authors: dogan a. Sci Rep. 2024 May 27;14(1):12123. doi: 10.1038/s41598-024-63096-7. Sci Rep. 2024. PMID: 38802494 Free PMC article.
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
Yıldırım HÇ, Mutlu E, Chalabiyev E, Özen M, Keskinkılıç M, Ön S, Çelebi A, Dursun B, Acar Ö, Kahraman S, Aykan MB, Kaman Ö, Doğan A, Erdoğan AP, Melisa Celayir Ö, Günenç D, Güven DC, Vedat Bayoğlu İ, Yavuzşen T, Hacıbekiroğlu İ, İnanç M, Kılıçkap S, Yalçın Ş, Aksoy S. Yıldırım HÇ, et al. Among authors: dogan a. Breast. 2022 Dec;66:85-88. doi: 10.1016/j.breast.2022.09.009. Epub 2022 Sep 30. Breast. 2022. PMID: 36208540 Free PMC article.
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.
Akdag G, Yildirim S, Dogan A, Yuksel Yasar Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, Turkoglu E, Alan O, Coban Kokten S, Isik D, Sever ON, Odabas H, Yildirim ME, Turan N. Akdag G, et al. Among authors: dogan a. Chemotherapy. 2024 Feb 16. doi: 10.1159/000537874. Online ahead of print. Chemotherapy. 2024. PMID: 38368871
Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data.
Sütcüoğlu O, Doğan A, Yilmaz F, Şahin AB, Şahin TK, Esen SA, Erol C, Üner A, Özet A, Turan N, Eraslan E, Deligönül A, Odabaş H, Günel N, Uçar G, Dede DŞ, Dizdar Ö, Çubukçu E, Öksüzoğlu ÖB, Emre Yildirim M, Yazici O, Özdemir N. Sütcüoğlu O, et al. Among authors: dogan a. Pancreas. 2023 Apr 1;52(4):e235-e240. doi: 10.1097/MPA.0000000000002238. Epub 2023 Oct 25. Pancreas. 2023. PMID: 37816170
1,515 results